Does Medicare Cover Zepbound? What the Medicare GLP-1 Bridge Changes

Who is eligible for the Medicare GLP-1 Bridge?

To qualify for the Medicare GLP-1 Bridge, a provider must attest that the beneficiary is at least 18 years old, is prescribed the drug to reduce excess body weight and maintain weight reduction alongside ongoing lifestyle modification, and at the time GLP-1 therapy was initiated had a BMI of 35 or higher; or a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above; or a BMI of 27 or higher with pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease.

Medicare GLP-1 Bridge clinical criteria must have been met at the time GLP-1 therapy was initiated, including for beneficiaries who started therapy before enrolling in Part D or before the July 1, 2026 launch; a beneficiary who started at a BMI of 37 and is now at 34 still qualifies under the BMI 35 criterion.

The exclusions matter as much as the thresholds. Beneficiaries with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH are ineligible for the Medicare GLP-1 Bridge even if they otherwise meet its clinical criteria, because those indications are eligible for regular Part D coverage; CMS directs them to obtain their GLP-1 through their Part D plan. If Zepbound is prescribed for sleep apnea, the Bridge is the wrong door; Part D is the right one.

Plan type matters too. To use the Medicare GLP-1 Bridge a beneficiary must be enrolled in a standalone Part D prescription drug plan or a Medicare Advantage coordinated care plan with drug coverage (HMO, HMO-POS, local or regional PPO); Special Needs Plans, employer/union group waiver plans, and the LI NET program are also eligible, while private fee-for-service plans, cost plans, PACE organizations, and similar plan types are not.

Which drugs does the Medicare GLP-1 Bridge cover?

As of August 2026 the Bridge covers three drugs for weight reduction — Foundayo, Wegovy (pen and pill), and the Zepbound KwikPen only. The Bridge is a CMS demonstration, not a permanent benefit. Its dates are fixed: July 1, 2026 through December 31, 2027.

Zepbound. Zepbound is tirzepatide. Zepbound is administered exclusively as a subcutaneous injection; the FDA label describes it only as 'injection, for subcutaneous use' and no oral dosage form of Zepbound is listed in the label. There is no Zepbound pill. Under the Bridge, the KwikPen is the only eligible presentation. Zepbound is also supplied as a single-patient-use KwikPen delivering four 0.6 mL doses per pen, available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per-dose strengths. If your current prescription is for a single-dose pen or a vial, it will need to be rewritten for the KwikPen to go through the Bridge.

Wegovy. Novo Nordisk states that all dose strengths of the Wegovy pen and pill are available for $50 per month to patients enrolled in an eligible Medicare Part D plan under the Medicare GLP-1 Bridge program, running July 1, 2026 through December 31, 2027, subject to prior authorization and a covered FDA-approved indication. Wegovy is semaglutide, a different drug from Zepbound, and it comes in both an injection and a daily tablet.

The current list. The drugs currently eligible under the Medicare GLP-1 Bridge are Foundayo, Wegovy (injection and tablets), and Zepbound (KwikPen only), when used to reduce excess body weight and maintain weight reduction; CMS updated the list on April 6, 2026 to add Foundayo and to clarify the KwikPen-only rule for Zepbound, and says the list can be updated again. Pen needles for the Zepbound KwikPen are not covered by the Medicare GLP-1 Bridge and must be purchased separately.

How much does Zepbound cost under the Medicare GLP-1 Bridge?

The Bridge copay is $50 per month for the Zepbound KwikPen, and CMS states it is unchanged regardless of Part D benefit phase, through December 31, 2027. That flat structure is the main point of the program. In a normal Part D year, what you pay for a drug can shift as you move through the benefit phases. Under the Bridge, the $50 figure holds. As of August 2026, CMS also spells out what the flat copay does not do: because Medicare GLP-1 Bridge drugs are furnished outside the Part D benefit, the Part D deductible does not apply, no part of the $50 copay counts toward the beneficiary's true out-of-pocket (TrOOP) costs, and no low-income subsidy is applied to the copay.

For comparison, Eli Lilly's wholesale acquisition cost (list price) for Mounjaro is $1,079.77 per carton of four single-dose pens, which is the same price at every strength from 2.5 mg/0.5 mL through 15 mg/0.5 mL, as of January 2025. Mounjaro is the same molecule as Zepbound (tirzepatide) marketed for type 2 diabetes. CMS and Lilly materials as of August 2026 do not state a separate list price for Zepbound.

Does Medicare cover Zepbound for sleep apnea?

Yes, potentially — but through regular Part D, not the Bridge. Part D's exclusion applies to drugs used for weight loss. It does not apply to other indications, which is why CMS routes sleep apnea patients away from the Bridge and to their Part D plan. For how plans decide in general, see does insurance cover GLP-1 weight loss medications. Zepbound is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

That makes OSA a separate conversation with your plan, and one that does not depend on the Bridge's dates. The OSA registration trials for Zepbound enrolled adults with moderate to severe OSA defined as an apnea-hypopnea index (AHI) of 15 or greater, in patients with obesity (BMI 30 kg/m2 or greater). Expect your plan to want a documented sleep study and diagnosis. For the obstructive sleep apnea indication, the recommended Zepbound maintenance dosage is 10 mg or 15 mg injected subcutaneously once weekly.

Whether any given Part D plan covers Zepbound for OSA, and on what terms, is plan-dependent. Check the formulary. A formulary is the list of prescription drugs covered by a prescription drug plan or other insurance plan offering prescription drug benefits. Expect a prior authorization. Preauthorization is a decision by a health insurer or plan that a health care service, treatment plan, prescription drug, or durable medical equipment is medically necessary. Preauthorization is not a promise that the health insurance plan will cover the cost of the service or drug.

How do I apply for the Medicare GLP-1 Bridge?

Five steps: confirm your plan type, document your eligibility, get the prescription written for the KwikPen, expect a prior authorization, and read the reason on any denial.

1. Confirm your plan type, not your plan's participation. Part D sponsors do not have to opt in to the Medicare GLP-1 Bridge for eligible beneficiaries to access the drugs; the Bridge operates outside the Part D benefit and CMS uses a single central processor for prior authorization, claims, and pharmacy payment in 2026. What matters is whether you are in an eligible plan type (see above).
2. Get your eligibility documented. Zepbound (tirzepatide) is FDA-indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. Your chart should show your BMI and any weight-related conditions. The Bridge uses the BMI and diagnosis thresholds listed above, measured at the time you started therapy. The documentation that gets a prior authorization approved is the same kind of record.
3. Ask your prescriber to write for the KwikPen. Not the vial. Not the single-dose pen. This is the most common way a Bridge claim fails at the pharmacy.
4. Expect prior authorization, and note that Bridge approvals last. A Medicare GLP-1 Bridge prior authorization, once approved, is valid for refills and dose changes through December 31, 2027 unless the beneficiary changes GLP-1 drugs. Measured states that many insurance plans require a prior authorization before they will cover brand-name GLP-1s such as Ozempic, Wegovy, Mounjaro, or Zepbound.
5. If denied, read the reason. When a plan denies a claim it is required to notify the enrollee of the reason the claim was denied. A denial for wrong formulation is fixed by a new script. A denial for missing documentation is fixed with records. For a regular Part D denial, Medicare's own appeal timeline applies, not the 180-day rule that governs most Marketplace and employer plans: an enrollee must request a Part D redetermination within 65 days of the denial notice. See how to appeal a GLP-1 denial for the general process, and confirm the deadline on your own denial notice. The Bridge itself is different: there is no appeals process under the Medicare GLP-1 Bridge; a prescriber may resubmit the prior authorization form with corrected or additional information.

What are my options if I don't qualify for the Bridge?

Paying cash is the remaining path if your plan does not participate, if you do not meet the Bridge criteria, or if you want to stay on vials.

Measured lists Zepbound as available "With and without insurance," with medication paid separately from membership. Measured lists Wegovy, Ozempic, Zepbound, and the Wegovy Pill at a membership price starting from $49/mo, with medication cost paid separately, as of August 2026. Measured's cash pay programs start at $119/month with medication and membership included, as of August 2026. Measured lists Compounded Tirzepatide as "No insurance required" with medication included in the membership price, from $219/mo, as of August 2026.

Compounded medications are not reviewed or approved by the FDA for safety or effectiveness. Measured states that compounded medications are not reviewed or approved by the FDA for safety or effectiveness, and that providers may prescribe them in certain cases to address patient-specific needs or when commercially available medications are not appropriate or available.

One honest caveat. For patients with commercial insurance, Measured performs a benefits check to determine which medications may be covered under the patient's plan. Measured's published materials as of August 2026 describe that service for commercial plans and do not describe a Medicare-specific benefits check. If you are on Medicare, ask Measured's care team directly what they can and cannot do with a Part D plan before you pay for anything.

What happens after the Bridge ends in December 2027?

The Bridge ends December 31, 2027. We do not have confirmed details on what follows it for Zepbound. One dated fact worth knowing: CMS negotiated a Medicare maximum fair price of $274 for a 30-day supply of the selected drug Ozempic; Rybelsus; Wegovy (Novo Nordisk Inc.), taking effect January 1, 2027. That negotiation covers semaglutide products, not Zepbound.

Last verified: August 21, 2026, against CMS and Medicare.gov Bridge pages (CMS provider FAQs last modified August 6, 2026). The Bridge is a moving target. If you are reading this after that date, recheck the program page before acting.